William Sargent Appointed to a Senior VP Position with a Private Pharmaceutical Company

September 17, 2020

William Sargent has been appointed Senior Vice President of Venatorx Pharmaceuticals.

William Sargent has over 25 years of biopharmaceutical industry experience, including multiple products and line extension launches. He will be responsible for designing and executing Venatorx’s commercial strategy across its portfolio of clinical and preclinical antibacterial and antiviral programs.

“Will has a proven track record of success and extensive expertise across a wide array of therapeutic areas, most notably in antibiotics,” said Christopher J. Burns, Ph.D., President and CEO of Venatorx. “As we develop our domestic and global go-to-market strategies and competitive analyses for our clinical and preclinical programs, it’s vital to have expertise like Will’s to drive our unique positioning, business intelligence and commercial plans forward.”

Prior to joining Venatorx, Mr. Sargent served as Vice President, Commercial Strategy at Nabriva where he led the launch and commercialization for Xenleta, a novel antibiotic approved for the treatment of community acquired bacterial pneumonia (CABP). Previously, Mr. Sargent held a variety of leadership roles at Auxilium Pharmaceuticals, including Vice President, Orthopedic Business Unit where he led the company’s sales and marketing teams advancing XIAFLEX® for the treatment of Dupuytren’s contracture and development of additional pipeline indications. Before Auxilium, Mr. Sargent was a biotechnology equities analyst at Bank of America and held multiple commercial roles at Amgen and Immunex. Mr. Sargent received his BA in Biology from Johns Hopkins University and an MBA from the University of Washington Foster School of Business.

“As antibiotic resistance continues to reach dangerous levels in the U.S. and around the world, it is an exciting time to join a company that has become a driving force for innovation and transformation in the anti-infective space,” said Mr. Sargent. “Venatorx has a robust portfolio of clinical and preclinical antibacterial and antiviral assets that each have a unique value proposition and potential for long-term health benefits for patients. I’m thrilled to join this dynamic, dedicated team and look forward to leading the company’s strategic commercial plans to foster growth and partnership opportunities for the company and its assets.”

Other Executives In the News

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

Dr A Burton Tripathi brings over two decades of Medical Device leadership experience, specializing in developing disruptive technologies, leading commercialization efforts, and facilitating M&A. Having recently served as CEO of TrueVision Systems Inc., he concluded the sale and integration of TrueVision with Alcon.
John Taylor brings more than 30 years of regulatory experience to his role at ELIQUENT, including a distinguished 20-year career at the U.S. Food and Drug Administration (FDA), where he served in multiple leadership positions, including as FDA’s Acting Deputy Principal Commissioner, FDA Counselor to the Commissioner, Acting Deputy Commissioner for Global Regulatory Operations and Policy, and Associate Commissioner for Regulatory Affairs.
Jennifer Riter comes to Kindeva from West Pharmaceutical where she spent the past 27 years in various technical and leadership roles, most recently serving as the Senior Director, Business and Technical Operations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version